Current status of artificial O2 carriers.
This article describes currently evaluated artificial O2 carriers, summarizes their efficacy, and discusses their side effects, based on and restricted to published data. For compounds in phase III testing, approximately 500 to 1000 patients have been dosed, and similar numbers of control patients have been investigated. For compounds in phase I or II testing, the number of patients dosed is significantly less. Unfortunately, there is a significant amount of nonpublished data, which renders the overall assessment difficult, and the direct comparison among different types of artificial O2 carriers is significantly limited by the virtual nonexistence of studies that directly compare different products.
Thyes
Caroline
C
Department of Anesthesiology, University Hospital Lausanne, (CHUV) CH-1011 Lausanne, Switzerland.
Spahn
Donat R
DR
D004655:Emulsions; D017707:Erythrocyte Transfusion; D005466:Fluorocarbons / Q000008:administration & dosage; D006454:Hemoglobins / Q000008:administration & dosage*; D006801:Humans; D008081:Liposomes; D010100:Oxygen / Q000008:administration & dosage*; D011994:Recombinant Proteins / Q000008:administration & dosage
D004655:Emulsions; D005466:Fluorocarbons; D006454:Hemoglobins; D008081:Liposomes; D011994:Recombinant Proteins; D010100:Oxygen